REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Chalcone: A new scaffold for the development of anti-epileptic medications

Neelam Mishra[1], Mayank Yadav[2], Avinash Chandra Tripathi[3]

[1*]Research Scholar, Department of Pharmaceutical Chemistry, Adarsh Vijendra Institute of Pharmaceutical Sciences Shobhit University, Gangoh, Saharanpur 247341
[2]Professor, Department of Pharmaceutical Chemistry, Adarsh Vijendra Institute of Pharmaceutical Sciences Shobhit University, Gangoh, Saharanpur 247341
[3]Professor, Department of Pharmaceutical Chemistry, RGS College of Pharmacy, Lucknow

***Corresponding Author:** Neelam Mishra
*****Department of Pharmaceutical Chemistry, Adarsh Vijendra Institute of Pharmaceutical Sciences Shobhit University, Gangoh, Saharanpur 247341

Abstract:
Flavonoids chalcones are a highly attended subclass of flavonoids having structural features and a β-unsaturated carbonyl system which have been identified to have the C band in the purine binding region and are promising molecules in the synthesis of new AEDs. Seizure disorder which presents as epilepsy – an episode of neurological dysfunction described by recurrent seizures – is still a major public health issue, especially in LMICs due to inadequate access to antiseizure medication. Even with the newly developed anti-seizure drugs and novel surgical approaches, nearly 30% of patients continue to be pharmacological treatment resistant thus the development of new pharmacological therapies. This review discusses the structural flexibility and pharmacological application of chalcones to overcome the drawbacks associated with first-generation AEDs. Exploring the possibility of altering chalcones' Functional Selectivity Profile for GABA receptors, as well as imp/map targets along with sodium and calcium channels could potentially lead to the development of a rational therapeutic strategy for drug-resistant epilepsy. Some investigators have also shown that certain chalcone derivatives have substantial anticonvulsant effects, better therapeutic profiles, and lesser harmful effects than standard AEDs. The superior formation of chalcones through microwave-assisted and green chemistry also supports the various strategies for fouling chalcones with improved therapeutic promise and bioavailability. It also provides information regarding the ability of chalcones as multi-target directed drugs, structure-activity relationships, and some issues related to the regulation of chalcones for clinical use. Despite being switchable phase II enzymes that possess diverse multi-parametric action potentials, chalcones present the possibility to design advanced AED drugs. Further discovery of pharmacodynamics, safety profiles, and factors determining the efficiency of such chalcones will remain the key to enhancing the probability of chalcones becoming effective epilepsy treatments.

Abbreviations
AEDs: Anti-Epileptic Drugs, ASMs: Anti-Seizure Medications, DBS: Deep Brain Stimulation, CNS: Central Nervous System, CT: Computed Tomography, EEG: Electroencephalogram, MRI: Magnetic Resonance Imaging, NF-κB: Nuclear Factor Kappa B, PI3K/Akt: Phosphoinositide 3-Kinase/Protein Kinase B, COX: Cyclooxygenase, LOX: Lipoxygenase, VGCCs: Voltage-Gated Calcium Channels, MES: Maximal Electroshock Seizure, AMPK: AMP-Activated Protein Kinase, LD_{50}: Median Lethal Dose, SAR: Structure-Activity Relationship, ROS: Reactive Oxygen Species, ED_{50}: Median Effective Dose

Introduction
Epilepsy is a non-communicable neurological condition that is defined by reoccurring seizures from an endogenous cause arising from electrical disturbances in the brain. It is estimated that about 1 in every 26 people will develop the condition at some point in his or her lifetime, and about 50 million people worldwide have the condition.(Waris et al. 2024)The WHO indicates that 5 million new cases are being diagnosed annually, and high-income countries are strategically different from low—and middle-income countries. The rate is around 49 per 100,000 annually in developed nations and around 139 for developing nations. This is due to things such as Indigenous diseases, road accidents, and disparities in facilities in the health sector.
This group of diseases has many etiological aspects, such as hereditary factors, head injuries, inflammations, and different intracerebral lesions. Signs are largely expressed in the form of seizures and they may be of severe or mild types with variation being noticed. Seizures may include muscle, jerk, spasms, stiffening, an altered level of consciousness, or a loss of consciousness depending on the area of the brain that has been affected. Epilepsy requires the client to undergo clinical assessments, and neuroimaging techniques such as magnetic resonance imaging (MRI) or computed tomography (CT) scans and electroencephalogram (EEG) to help the physician monitor brain activity. (Waris et al. 2024; Schmidt 2009)
Although epilepsy can be well controlled by individuals by means of ASMs and other treatments, many challenges remain to be met that affect epilepsy care, especially in developing countries. The problems of the treatment adequacy ratio, or the observational gap, whereby a considerable number of patients with epilepsy remain without proper care, are still

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

relevant. It is concerning that this gap is particularly significant in poor and middle-income countries where only a quarter of patients may seek appropriate treatment owing to factors including lack of access to proper medicines and healthcare. (Issaoui and Koçak 2023)

Current Treatment Options and Limitations

Anti-Seizure Medications (ASMs): Anti-seizure agents or anti-epileptic drugs are still the mainstream therapy for epilepsy; about 60 to 70% of patients enjoy seizure freedom with the medication. However, between 30% of people with epilepsy remain unresponsive to antiseizure medications, hence developing drug-resistant seizures. This gives these individuals higher chances of getting an injury and getting other related disorders such as depression and anxiety besides getting a lower quality of life. Some of the challenges, which accompany ASM use include the following. ASM's use in LAMI countries is a paradox with less than 50% availability and even patients who are literally exposed to it cannot access it. Issues like sleepiness, vertigo, and teratogenic effects when pregnant make it hard to adhere to these treatment regimens. However, accessibility constraints are compounded by economic barriers and limited health literacy. (Depondt 2006; Waris et al. 2024)

Surgical Interventions: Surgical options, such as resection of the seizure focus, offer relief for individuals with drug-resistant epilepsy. Despite their potential effectiveness, these interventions are underutilized. Limited access to specialized care and facilities, along with the need for comprehensive pre-surgical evaluations—including advanced neuroimaging and neuropsychological assessments—restricts their availability, particularly in resource-constrained settings.(Schmidt and Schachter 2014; Issaoui and Koçak 2023)

Emerging Therapies: Innovative treatments like deep brain stimulation (DBS) and responsive neurostimulation present promising options for patients with drug-resistant epilepsy. However, these treatments are still considered experimental and are associated with risks from invasive surgical procedures. Their high costs and the need for highly skilled practitioners further limit accessibility, particularly in lower-income settings.(Depondt 2006)

Future Directions

Enhanced Healthcare Access: Strengthening healthcare systems in resource-limited settings is essential to improve ASM availability and access to specialized care. Addressing economic and awareness barriers can further ensure better adherence and equity in epilepsy management.(Issaoui and Koçak 2023)

Innovation in Treatment: Research and development of safer, more effective ASMs with fewer side effects are critical. Advancing surgical and neurostimulation techniques to make them safer, more cost-effective, and widely accessible will expand their impact on a broader patient population.(Waris et al. 2024)

Global Collaboration: International efforts to address disparities in epilepsy care are vital. Collaborative research into the underlying mechanisms of epilepsy and individual treatment responses will facilitate the development of tailored solutions and equitable treatment options.(Schmidt and Schachter 2014) While epilepsy is a manageable condition for many, addressing its treatment limitations and care disparities remains a significant challenge. Through coordinated efforts, the goal of improved outcomes and quality of life for all individuals living with epilepsy can be achieved.(Schmidt 2009)

Chalcones: Structure and Pharmacological Relevance:



Fig no 1: Structures of chalcone (1,3-diaryl-2-proper-1-one) and its substituted derivatives: 4-hydroxy chalcone (-OH group on ring A), 4-methoxy chalcone (-OCH_3 group on ring B), and 4-nitro chalcone (-NO_2 group on ring B),

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Chalcones are a class of organic compounds that belong to the flavonoid family, characterized by their unique structure as 1,3-diaryl-2-propen-1-ones. This structure consists of two aromatic rings (designated as the A and B rings) connected by a three-carbon α,β-unsaturated carbonyl system. The general formula for chalcones is $C_{15}H_{12}O$, whose simplest form is phenyl-2-propen-1-one. The A ring is typically a phenyl group attached to the carbonyl carbon, while the B ring is another aromatic system. This structural arrangement allows chalcones to exhibit various biological activities due to the reactivity of the α,β-unsaturated carbonyl moiety, which can interact with nucleophiles in biological systems. (Aksöz and Ertan 2011; Zhuang et al. 2017a)

Chalcones are widely distributed in nature, and found in various plants including fruits, vegetables, and teas. They serve as precursors to many biologically significant compounds and play essential roles in plant metabolism. The biosynthesis of chalcones occurs through the action of chalcone synthase, an enzyme that catalyzes the condensation of malonyl-CoA and a suitable aromatic precursor.(Tomás-Barberán and Clifford 2000) This biosynthetic pathway highlights their importance not only as secondary metabolites but also as key intermediates in the synthesis of more complex flavonoids. Chalcones represent a significant area of interest in pharmacology due to their diverse biological activities and therapeutic potential. Their unique structural features facilitate various interactions within biological systems, leading to numerous health benefits ranging from anticancer effects to anti-inflammatory and antimicrobial activities. Continued research into chalcone derivatives is essential for unlocking their full pharmacological potential and addressing current limitations in drug development. The ongoing exploration of their structure-activity relationships will likely yield novel compounds with enhanced efficacy against various diseases.(Mezgebe, Melaku, and Mulugeta 2023a; Zhuang et al. 2017a; Aksöz and Ertan 2011)

Basic Structure of Chalcones

Chalcones are a significant class of flavonoids defined as 1,3-diaryl-2-propen-1-ones. Their basic structure consists of two aromatic rings (A and B) linked by a three-carbon α,β-unsaturated carbonyl system. The General Formula of Chalcones is $C_{15}H_{12}O$ This formula highlights that chalcones contain 15 carbon atoms, 12 hydrogen atoms, and one oxygen atom. The structural features of chalcones include two key components: aromatic rings and a three-carbon chain. The A ring is typically a phenyl group (C_6H_5) attached to one end of the chain, while the B ring represents another aromatic group, which can either be a phenyl or a substituted phenyl ring. This variation in the B ring contributes to the structural diversity and functional versatility of chalcones. The three-carbon chain forms the central backbone of chalcones and includes a double bond (C=C) between the second and third carbon atoms, along with a carbonyl group (C=O) attached to the second carbon. This configuration results in an α,β-unsaturated ketone system, which is a defining feature of chalcones and plays a crucial role in their biological activity.(Zhuang et al. 2017)



Fig No 2: Chemical structures of chalcone (1,3-diaryl-2-propen-1-one) and its cis and trans isomers. The chalcone structure consists of two aromatic rings (A and B) connected by an α,β-unsaturated carbonyl moiety. The cis isomer has substituents on the same side of the double bond, while the trans isomer has them on opposite sides, highlighting the impact of stereochemistry on the molecule's geometry.

Chalcones exhibit isomerism due to the presence of the double bond (C=C) in their structure, allowing them to exist in both cis and trans isomeric forms. Among these, the trans isomer is more thermodynamically stable and is the form most

commonly observed under standard conditions. The biological significance of chalcones lies in their distinctive open-chain structure, which enables effective interactions with biological macromolecules. A key feature of chalcones is their α,β-unsaturated carbonyl system, which serves as a reactive site, facilitating interactions with proteins and nucleic acids. This structural arrangement is fundamental to the diverse range of biological activities exhibited by chalcones, including antimicrobial, anti-inflammatory, anticancer, and antioxidant effects.(Go, Wu, and Liu 2005)

Chalcones exhibit remarkable structural variations that significantly impact their chemical and pharmacological properties. These variations include simple chalcones, the classical form with no additional substituents, and hybrid chalcones, which integrate functional groups or heterocycles into their structure. Hybrid chalcones allow for extensive modifications, enabling the development of derivatives with enhanced biological activities.(Salehi et al. 2021; Zhuang et al. 2017)

Notable examples of chalcone derivatives include bichalcones, containing two chalcone moieties within a single molecule, and dihydrochalcones, which lack the α,β-unsaturated double bond due to reduction. These structural adaptations confer distinct properties and broaden the range of biological activities of chalcones.(Mezgebe, Melaku, and Mulugeta 2023; Salehi et al. 2021)

The unique architecture of chalcones, defined by their open-chain configuration linking two aromatic rings through an α,β-unsaturated carbonyl system, forms the basis of their diverse biological roles. This framework not only makes chalcones critical precursors in flavonoid biosynthesis but also establishes their significance in drug discovery and development. With their wide-ranging pharmacological effects, including antimicrobial, anticancer, and antioxidant properties, chalcone derivatives are valuable candidates in medicinal chemistry. Ongoing research into these derivatives continues to unveil their potential in therapeutic applications.(Dhaliwal et al. 2022; Mezgebe, Melaku, and Mulugeta 2023; Salehi et al. 2021)

Pharmacological Activities

Anticancer Properties: Chalcones have been extensively studied for their anticancer properties. Research indicates that they can induce apoptosis (programmed cell death) in various cancer cell lines by modulating key signaling pathways such as the NF-κB and PI3K/Akt pathways. For example, specific chalcone derivatives have shown effectiveness against breast cancer cells by downregulating anti-apoptotic proteins and upregulating pro-apoptotic factors. These compounds also exhibit cell cycle arrest at different phases, contributing to their potential as chemotherapeutic agents.(Mezgebe, Melaku, and Mulugeta 2023a; Zhuang et al. 2017)

Anti-inflammatory Effects: The anti-inflammatory effects of chalcones are significant and have been attributed to their ability to inhibit pro-inflammatory cytokines and enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). Studies have demonstrated that chalcone derivatives can reduce inflammation in models of arthritis and other inflammatory diseases by blocking the NF-κB signaling pathway. This action not only alleviates symptoms but also addresses underlying inflammatory processes.

Antimicrobial Activity: Chalcones possess notable antimicrobial properties against a range of pathogens, including bacteria, fungi, and protozoa. Their mechanism often involves disrupting microbial cell membranes or inhibiting essential metabolic pathways within microorganisms. For instance, certain chalcone derivatives have demonstrated effectiveness against resistant strains of bacteria such as Staphylococcus aureus and Escherichia coli.(Mezgebe, Melaku, and Mulugeta 2023) Additionally, some studies highlight their antifungal activity against Candida species, suggesting their potential use in treating various infections.

Antidiabetic Effects: Recent research has explored the antidiabetic potential of chalcones. Certain derivatives have been shown to enhance insulin sensitivity and lower blood glucose levels in diabetic models. Mechanistically, these compounds may activate AMP-activated protein kinase (AMPK), which plays a crucial role in regulating glucose metabolism. This positions chalcones as promising candidates for developing new treatments for diabetes management.(Dhaliwal et al. 2022)

Mechanisms of Anti-Epileptic Action: The treatment of epilepsy primarily focuses on restoring the balance between excitatory and inhibitory neurotransmission in the brain. Various mechanisms are involved in the action of anti-epileptic drugs (AEDs), including GABAergic modulation, sodium channel inhibition, and calcium channel modulation. Each of these mechanisms plays a critical role in controlling seizure activity and maintaining neuronal stability.(Dhaliwal et al. 2022a) The mechanisms underlying anti-epileptic action are multifaceted, involving intricate interactions between various neurotransmitter systems. GABAergic modulation enhances inhibitory signaling; sodium channel inhibition stabilizes neuronal excitability; and calcium channel modulation regulates neurotransmitter release. Understanding these mechanisms is crucial for developing more effective therapies for epilepsy management and improving patient outcomes.

GABAergic Modulation: Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the central nervous system (CNS) and plays a vital role in modulating neuronal excitability. It is essential for maintaining the excitation-inhibition balance that underpins normal brain function. In epilepsy, disruptions in GABAergic transmission result in increased neuronal excitability, leading to seizure activity. GABA mediates its effects primarily through two types of receptors: **$GABA_A$** and **$GABA_B$**. GABAA_AA receptors are ionotropic and facilitate fast inhibitory synaptic transmission by allowing chloride ions to enter neurons, causing hyperpolarization and reducing the likelihood of action potential generation. In contrast, $GABA_B$ receptors are metabotropic and mediate slower inhibitory responses by

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

increasing potassium efflux and inhibiting calcium influx, further dampening neuronal excitability. These mechanisms make the GABAergic system a critical target for anti-epileptic drugs (AEDs).(Olsen and Sieghart 2009) Benzodiazepines and barbiturates enhance inhibitory neurotransmission by increasing the frequency or duration of $GABA_A$ receptor openings, effectively suppressing seizure activity. Additionally, drugs like vigabatrin and tiagabine modulate synaptic GABA levels; vigabatrin inhibits GABA transaminase to prevent GABA degradation, while tiagabine blocks GABA reuptake, prolonging its availability in the synapse. (Treiman 2001)
Abnormalities in GABAergic function are widely observed in epilepsy models, where reduced GABA-mediated inhibition correlates with increased seizure frequency. For example, changes in the expression or function of $GABA_A$ receptor subunits can influence both seizure susceptibility and severity. This underscores the therapeutic importance of targeting the GABAergic system to manage epilepsy effectively. By enhancing GABAergic transmission or correcting associated dysfunctions, AEDs help restore the excitation-inhibition balance, reducing neuronal hyperexcitability and controlling seizures. These findings highlight the critical role of the GABAergic system in both the pathophysiology of epilepsy and its treatment.(Treiman 2001; Meldrum 2000)

Sodium Channel Inhibition
Sodium channels are essential for the generation and propagation of action potentials in neurons. Anti-epileptic drugs often target voltage-gated sodium channels to stabilize neuronal membranes and prevent excessive excitatory activity associated with seizures. By inhibiting these channels, AEDs can reduce the excitability of neurons, thereby decreasing the likelihood of seizure initiation.(Shorvon 2011; Benarroch 2021)
Several commonly used AEDs, such as phenytoin, carbamazepine, and lamotrigine, exert their effects through sodium channel blockade. These drugs preferentially bind to the inactive state of sodium channels, prolonging their recovery time from inactivation and thereby reducing neuronal firing rates. This mechanism is particularly effective in controlling focal seizures and generalized tonic-clonic seizures.(Emilio Perucca, White, and Bialer 2023; Catterall 2014)
Research has shown that alterations in sodium channel expression or function can contribute to epileptogenesis. For instance, increased expression of specific sodium channel subtypes has been linked to enhanced neuronal excitability in epileptic tissues. Moreover, genetic mutations affecting sodium channel function have been implicated in certain inherited forms of epilepsy, further underscoring the significance of sodium channel modulation in seizure control.(Meldrum 1996; Waxman and Zamponi 2014)

Calcium Channel Modulation
Calcium channels play a critical role in neurotransmitter release and neuronal excitability. Modulation of calcium channels is another important mechanism by which anti-epileptic drugs exert their effects. There are several types of calcium channels, but voltage-gated calcium channels (VGCCs), particularly the N-type and T-type channels, are most relevant to epilepsy. (Richardson, Petrou, and Bryson 2024) AEDs such as ethosuximide specifically target T-type calcium channels, which are involved in generating rhythmic burst firing in thalamic neurons—a process that can contribute to absence seizures. By inhibiting T-type calcium channels, ethosuximide reduces the abnormal oscillatory activity associated with these seizures. In addition to T-type channels, N-type calcium channels are also significant targets for AEDs like gabapentin and pregabalin. These drugs bind to auxiliary subunits of N-type calcium channels, inhibiting neurotransmitter release from presynaptic terminals and thus reducing excitatory neurotransmission. (Emilio Perucca, Bialer, and White 2023; Fritschy 2008)This mechanism is particularly beneficial for managing neuropathic pain but also contributes to their efficacy as adjunctive treatments for epilepsy. Overall, modulation of calcium channels represents a vital strategy for controlling seizure activity by decreasing excessive excitatory neurotransmission associated with epilepsy.(Lu et al. 2019; Treiman 2001)

Table 1: Overview of Mechanisms Involved in Epileptic Seizures and Chalcone Targets

Mechanism	Description	Chalcone Targets	References
GABAergic Modulation	GABA is the primary inhibitory neurotransmitter in the CNS. Enhancing GABAergic transmission can reduce seizure activity.	Chalcones have been shown to enhance GABA receptor activity, increasing inhibitory neurotransmission.	(Treiman 2001).
Sodium Channel Inhibition	Sodium channels are crucial for action potential generation. Inhibition stabilizes neuronal membranes and reduces excitability.	Certain chalcones inhibit sodium channels, thereby decreasing neuronal excitability and seizure frequency.	(Mohamed and Abuo-Rahma 2020)
Calcium Channel Modulation	Calcium channels facilitate neurotransmitter release and neuronal excitability. Modulating these channels can control seizures.	Chalcones can modulate calcium channels, particularly T-type channels, reducing excitatory neurotransmission.	(Mahapatra, Bharti, and Asati 2017)

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Pharmacological Profiles of Chalcone Derivatives in Epilepsy:
Chalcones, a class of flavonoids, have emerged as potential therapeutic agents for various medical conditions, including epilepsy. Their pharmacological profiles are characterized by diverse mechanisms of action, particularly in modulating neurotransmitter systems and ion channels.

1. Anticonvulsant Activity of Chalcone Derivatives
Recent research has demonstrated that several chalcone derivatives exhibit significant anticonvulsant activity in various experimental models. A study synthesized a series of chalcone derivatives containing a coumarin moiety and evaluated their effects using classic anticonvulsant mouse models. The results indicated that compounds such as 2a, 2c, and 2h showed promising anticonvulsant activities at a dosage of 30 mg/kg in the maximal electroshock seizure test (MEST). These compounds not only reduced seizure frequency but also exhibited antidepressant properties, suggesting their potential as adjunct therapies for patients with epilepsy and comorbid depression.(Verma, Srivastava, and Pandey 2018; Alka N. Choudhary, Arun Kumar, and Vijay Juy 2012)

2. Mechanistic Insights
The anticonvulsant effects of chalcone derivatives are believed to be mediated through several mechanisms, including GABAergic modulation and ion channel interactions. Chalcones can enhance GABAergic transmission by increasing the activity of $GABA_A$ receptors, which play a crucial role in inhibitory neurotransmission in the brain. This modulation is vital for restoring the excitation-inhibition balance disrupted in epileptic conditions. Additionally, some studies suggest that chalcones may inhibit voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing excitability. This action is particularly relevant for controlling focal seizures and generalized tonic-clonic seizures. The ability to target multiple pathways makes chalcones versatile agents in epilepsy management.(Gaonkar and Vignesh 2017; Alka N. Choudhary, Arun Kumar, and Vijay Juy 2012)

3. Specific Chalcone Derivatives
A notable study investigated the synthesis and anticonvulsant activity of various substituted chalcones and their derivatives. The research found that these compounds exhibited significant biological properties, including anticonvulsant activity comparable to standard drugs. For example, specific derivatives demonstrated enhanced efficacy in reducing seizure activity in animal models, indicating their potential as effective anti-epileptic agents. Moreover, another study highlighted the role of protrudin, a neural membrane protein that regulates $GABA_A$ receptor-mediated synaptic transmission. Overexpression of protrudin was associated with increased GABAergic inhibitory currents and decreased seizure frequency in mouse models. This suggests that chalcone derivatives targeting similar pathways could enhance GABA receptor function and provide therapeutic benefits for epilepsy.(Alka N. Choudhary, Arun Kumar, and Vijay Juy 2012)

4. Safety and Tolerability
The safety profiles of chalcone derivatives are also an essential consideration in their development as anti-epileptic agents. Studies have shown that many chalcone compounds exhibit low toxicity levels while maintaining significant anticonvulsant efficacy. For instance, acute toxicity studies have indicated that certain chalcones have high tolerability with minimal adverse effects at therapeutic doses.(Verma, Srivastava, and Pandey 2018)

Types and Modifications of Chalcone Derivatives
Chalcones, defined as 1,3-diaryl-2-propen-1-ones, are highly versatile compounds in medicinal chemistry, recognized for their significant pharmacological activities. Their structure consists of an α,β-unsaturated carbonyl system linking two aromatic rings, which provides a flexible framework for structural modifications. These modifications not only enhance their biological properties but also expand their scope in drug development. Chalcones can be broadly classified into two main categories: simple or classical chalcones and hybrid chalcones.(Gaonkar and Vignesh 2017)

- **Simple or Classical Chalcones:** Simple or classical chalcones are the fundamental form of chalcones, characterized by their core structure of 1,3-diaryl-2-propen-1-one. These compounds are abundantly found in nature and serve as precursors for more complex flavonoids and isoflavonoids. Their pharmacological activities are often associated with the inherent chemical properties of the α,β-unsaturated carbonyl system, as well as the nature of substituents on the aromatic rings. These chalcones are particularly valued for their simplicity and serve as a starting point for designing more specialized derivatives. (Tukur et al. 2022)
- **Hybrid Chalcones:** Hybrid chalcones represent a diverse group of derivatives formed by incorporating additional functional groups or structural elements into the classical chalcone framework. These modifications can significantly alter the properties of the molecules, leading to improved or novel biological activities. A notable example is bi-chalcones, which consist of two chalcone units linked together, enhancing their molecular complexity. Another example is dihydrochalcones, which feature a reduced double bond in the α,β-unsaturated system. Other structural variations, such as fused chalcones or chalcone mimics, retain the core pharmacophore while diverging from the traditional chalcone structure, thereby expanding their potential applications. These classifications underscore the

importance of chalcones as both naturally occurring bioactive compounds and templates for synthetic modification, highlighting their role in the development of new therapeutic agents.(Elkanzi et al. 2022)

Structural Modifications: The structural flexibility of chalcones allows for a wide range of modifications that can enhance their pharmacological properties, making them attractive candidates for drug development. Among the most common and impactful structural modifications are substituent variations, heterocyclic incorporation, and the creation of fused structures. These modifications are strategically employed to improve the biological activity of chalcone derivatives and expand their therapeutic applications.

- **Substituent variations** play a crucial role in modulating the biological activity of chalcone derivatives. The introduction of different substituents on the aromatic rings of chalcones can significantly influence their pharmacological effects. Electron-donating groups, such as methoxy or alkyl groups, tend to enhance the electron density on the aromatic rings, which can increase the reactivity and biological activity of chalcones. On the other hand, electron-withdrawing groups, such as nitro or halogen substituents, may reduce the electron density, potentially decreasing the compound's activity. This fine-tuning of activity through substituent variations allows for the design of chalcone derivatives with specific therapeutic targets. (Gaonkar and Vignesh 2017)
- **Heterocyclic incorporation** has also become a prominent strategy in chalcone modification. Advances in synthetic chemistry have enabled the introduction of heterocycles—such as nitrogen, oxygen, or sulfur-containing rings—into chalcone structures. These modifications often enhance the biological activity of the compounds, such as improving antibacterial, antifungal, and anticancer properties. For example, chalcones incorporating imidazole or benzimidazole rings have been shown to exhibit significant inhibitory activity against monoamine oxidase (MAO) enzymes, which are implicated in a variety of neurological disorders. The incorporation of heterocyclic groups thus allows chalcones to interact with biological targets in novel ways, expanding their therapeutic potential.(Tukur et al. 2022)
- **Fused structures** represent another important modification that enhances the biological properties of chalcones. In these derivatives, the chalcone backbone is fused with other aromatic or heterocyclic ring systems, creating a more complex molecular structure. Fused chalcones have demonstrated increased potency against various biological targets compared to their non-fused counterparts. These fused systems can often enhance the compound's ability to bind to receptors or enzymes, improving efficacy in therapeutic applications. As a result, fused chalcones are being explored for their enhanced activity against cancer, infectious diseases, and other conditions. These structural modifications highlight the adaptability of chalcones, making them highly customizable for a variety of pharmacological applications. By carefully manipulating their structure, researchers can design chalcone derivatives with enhanced biological activities, potentially leading to the development of novel therapeutic agents.(Elkanzi et al. 2022)

Synthesis Methods

The synthesis of chalcone derivatives can be achieved through a variety of methods, each offering distinct advantages in terms of yield, reaction time, and versatility. Among the most common and widely used techniques are the Claisen-Schmidt condensation, microwave-assisted synthesis, and several other synthetic approaches that facilitate the efficient formation of chalcone structures.

Claisen-Schmidt condensation

The Claisen-Schmidt condensation is one of the most traditional and commonly used methods for synthesizing chalcones. This reaction involves the condensation of an aromatic aldehyde with an acetophenone derivative under basic conditions, typically using sodium hydroxide or potassium hydroxide as the catalyst. The process results in the formation of the α,β-unsaturated carbonyl structure that characterizes chalcones. This method is favored for its simplicity and well-established procedure, making it a staple in chalcone synthesis.(Elkanzi et al. 2022; Alka N. Choudhary, Arun Kumar, and Vijay Juy 2012)

Synthetic Methods for Chalcone Derivatives

The synthesis of chalcone derivatives involves various chemical methods, with the **Claisen-Schmidt condensation** being one of the most commonly used techniques.

1. Claisen-Schmidt Condensation

The **Claisen-Schmidt condensation** is a classic method for synthesizing chalcones, involving the condensation of an aromatic aldehyde with an acetophenone derivative in the presence of a strong base.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Reaction Scheme for Claisen-Schmidt Condensation:



$$\text{Aromatic Aldehyde (PhCHO)} + \text{Acetophenone } (C_6H_5COCH_3) \xrightarrow{\text{NaOH}} \text{Chalcone} + H_2O$$

1. **Step 1**: An aromatic aldehyde (e.g., benzaldehyde) reacts with an acetophenone (e.g., phenylacetone).
2. **Step 2**: The base (NaOH) deprotonates acetophenone to form an enolate ion.
3. **Step 3**: The enolate ion attacks the carbonyl carbon of the aldehyde, leading to the formation of chalcone.
4. **Step 4**: The reaction is completed with the elimination of water.

Microwave-assisted synthesis:
Microwave-assisted synthesis has gained significant attention in recent years due to its ability to accelerate reactions and produce high yields in much shorter reaction times compared to conventional heating methods. By applying microwave irradiation, the reaction mixtures are heated more uniformly and efficiently, which often leads to faster completion of the reaction. This method has proven particularly effective for synthesizing chalcone derivatives in a green chemistry context, as it reduces the need for harsh solvents and prolonged reaction times, making it an environmentally friendly option.

Reaction Scheme for Microwave-Assisted Synthesis:



$$\text{Aromatic Aldehyde (PhCHO)} + \text{Acetophenone } (C_6H_5COCH_3) \xrightarrow{\text{Microwave}} \text{Chalcone} + H_2O$$

1. **Step 1**: The reaction mixture is placed in a microwave reactor with the aromatic aldehyde and acetophenone.
2. **Step 2**: Microwave energy heats the mixture uniformly and rapidly.
3. **Step 3**: The base (usually NaOH or KOH) catalyzes the condensation to form chalcone.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

4. **Step 4**: Water is eliminated in the final step, and the chalcone product is obtained in a short time with high yield.

One-Pot Synthesis
One-pot synthesis is a highly efficient technique where all reactants are added in a single reaction vessel, eliminating the need for intermediate steps and purification between reactions.
Reaction Scheme for One-Pot Synthesis:



$$\text{Aromatic Aldehyde (PhCHO)} + \text{Acetophenone } (C_6H_5COCH_3) \xrightarrow{\text{NaOH, Ethanol}} \text{Chalcone} + H_2O$$

1. **Step 1**: Both the aldehyde and acetophenone, along with the base (NaOH), are mixed in an ethanol solvent.
2. **Step 2**: The condensation reaction proceeds to form chalcone in a single step.
3. **Step 3**: Water is eliminated as a byproduct, and the chalcone product is purified.

In addition to these methods, several other synthetic approaches have been explored to produce chalcones under mild and efficient conditions. For instance, Friedel-Crafts acylation reactions can be employed to directly acylate an aromatic compound with an acetyl group, followed by an appropriate condensation to form chalcones. Another notable approach involves the use of ionic liquids or PEG-based solvents. These alternative solvents offer several advantages, such as reducing the need for volatile organic solvents, enhancing reaction selectivity, and improving reaction yields under milder conditions. Together, these various synthetic techniques allow for the production of chalcones and their derivatives with high efficiency, improved yields, and under environmentally friendly conditions, supporting their continued development for pharmaceutical and industrial applications.(Verma, Srivastava, and Pandey 2018; Gaonkar and Vignesh 2017)

Structure-Activity Relationship (SAR) of Chalcones
The structure-activity relationship (SAR) of chalcones is a pivotal area of research that aims to understand how the structural features of chalcones influence their biological activities and pharmacological properties. This understanding is crucial for the rational design of more potent chalcone derivatives with enhanced therapeutic potential. The SAR of chalcones is influenced by various factors, including the core structure, modifications on the aromatic rings, the incorporation of heterocyclic groups, stereochemistry, and their pharmacological implications. The structure-activity relationship of chalcones is a dynamic and evolving field that combines synthetic chemistry with pharmacology to optimize drug design. By understanding how structural modifications influence biological activity, researchers can develop chalcone derivatives with enhanced therapeutic potential. With continued exploration in this area, chalcones hold great promise as the basis for novel compounds with improved efficacy, safety profiles, and broad therapeutic applications.(Dhaliwal et al. 2022a)

Core Structure and Functional Groups
The core structure of chalcones consists of an α,β-unsaturated carbonyl group (C=O) attached to two aromatic rings. This structure is fundamental to their biological activity because the α,β-unsaturated carbonyl group is highly reactive, enabling interactions with various biological targets such as enzymes, receptors, and DNA. The presence and placement of functional groups on the aromatic rings can dramatically alter the pharmacological properties of chalcone derivatives. For example, electron-donating groups (e.g., methoxy, alkyl groups) on the A ring typically enhance the biological activity by increasing electron density, thus making the chalcone more reactive. Conversely, electron-withdrawing groups (e.g., nitro, halogens) on the aromatic rings can reduce the activity by decreasing electron density, which may influence the reactivity of the α,β-unsaturated system.(Moreira et al. 2021)

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Modifications on the A and B Rings

Modifications on the A and B rings of chalcones are essential for optimizing their biological activity. Studies have shown that specific substitutions on these rings can enhance chalcones' anticancer, antimicrobial, and anti-inflammatory effects. For instance, the introduction of a methoxy group at the para position of the A ring has been linked to increased cytotoxicity against cancer cell lines. Similarly, the types of substituents on the B ring can impact the potency and selectivity of chalcone derivatives for particular biological targets. Modifications on the B ring can affect the molecule's ability to bind to enzymes, receptors, or other biomolecules, thereby enhancing its therapeutic potential.(Tukur et al. 2022)

Heterocyclic Chalcones

Recent advancements in the synthesis of chalcone derivatives have led to the incorporation of heterocyclic moieties, which significantly enhance the biological activity of chalcones. The addition of five-membered N-heterocycles such as imidazole or benzimidazole to the chalcone structure has shown promising results in inhibiting enzymes like monoamine oxidase (MAO), which are involved in neurodegenerative conditions like depression and anxiety. Heterocyclic chalcones often exhibit better solubility and bioavailability compared to their non-heterocyclic counterparts, which is crucial for their effectiveness as drugs. This modification not only broadens the chemical space but also improves the pharmacokinetic properties of the chalcone derivatives, making them more suitable for therapeutic applications.(Moreira et al. 2021)

Influence of Stereochemistry

Stereochemistry plays a crucial role in the biological activity of chalcone derivatives. The configuration around the double bond in the α,β-unsaturated carbonyl system can significantly impact the compound's binding affinity to its biological targets. Studies suggest that trans-chalcones generally exhibit higher biological activity than their cis counterparts due to the better alignment of the molecular structure with target sites. This is particularly important when designing chalcone derivatives for specific receptor binding or enzyme inhibition. Therefore, stereochemical considerations are vital in the design and synthesis of chalcones to optimize their interaction with biological targets and enhance their therapeutic efficacy.(Tukur et al. 2022b; Elkanzi et al. 2022)

Pharmacological Implications

Understanding the SAR of chalcones has profound pharmacological implications. By systematically modifying the core structure and functional groups of chalcones, researchers can design compounds with enhanced efficacy against specific diseases. For instance, certain chalcone derivatives have demonstrated potent anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes, while others have shown strong antibacterial activity against resistant bacterial strains. The ability to manipulate the chalcone structure to target specific biological pathways or diseases is invaluable in the development of novel therapeutic agents. SAR studies enable the rational design of chalcone-based drugs that can offer improved therapeutic outcomes, with the potential to treat a wide range of conditions, including cancer, infections, and neurological disorders.(Gaonkar and Vignesh 2017)

Table 2: SAR of Key Chalcone Derivatives with Anti-Epileptic Properties

Chalcone Derivative	Structure	Key Modifications	Anti-Epileptic Activity	References
Structure 1	Para-Methoxy Chalcone:	Para-methoxy substitution on A ring	Showed significant anticonvulsant activity in MES test (ED_{50} = 30 mg/kg)	(Sharma et al. 2013; Elkanzi et al. 2022)
Structure 2	Para-Nitro Chalcone:	4-Nitro substitution on B ring	Enhanced GABA A receptor activity, reducing seizure frequency	(Liu et al. 2022)
Structure 3	Imidazole Chalcone:	Incorporation of imidazole ring	Inhibited sodium channels, stabilizing neuronal membranes	(Tukur et al. 2022b)
Structure 4	Dihydroxy Chalcone:	2,4-Dihydroxy substitution on A ring	Exhibited potent anti-inflammatory effects, contributing to seizure control	(Elkanzi et al. 2022)
Structure 5	Benzyl Chalcone:	Benzyl substitution on B ring	Demonstrated significant reduction in seizure activity in animal models	(Sharma et al. 2013)

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024



- **Chalcone Derivative 1**: This compound contains a para-methoxy group on the A ring. The methoxy substitution enhances the lipophilicity of the molecule, improving its ability to cross the blood-brain barrier. In experimental models, it has been shown to exhibit significant anticonvulsant activity in the maximal electroshock seizure (MES) test, with an effective dose (ED_{50}) of 30 mg/kg. This suggests its potential as a candidate for further development in the treatment of epilepsy.(Elkanzi et al. 2022; Sharma et al. 2013)
- **Chalcone Derivative 2**: In this derivative, a nitro group is substituted at the para position of the B ring. This modification enhances the compound's interaction with GABA_A receptors, which are crucial in regulating inhibitory neurotransmission. By increasing GABA_A receptor activity, this chalcone derivative reduces seizure frequency in experimental models, offering a promising approach to enhancing the inhibitory effects in the brain and controlling seizure episodes.(Liu et al. 2022)
- **Chalcone Derivative 3**: This derivative's key structural feature is the incorporation of an imidazole ring. This modification grants the compound enhanced sodium channel inhibition properties, which help stabilize neuronal membranes and reduce excitability. As a result, the compound effectively controls seizures by preventing abnormal neuronal firing, a key mechanism in epileptic activity.(Tukur et al. 2022)
- **Chalcone Derivative 4**: This compound features dihydroxy substitutions on the A ring, contributing to its potent anti-inflammatory effects. Reducing inflammation in neuronal tissues plays a crucial role in mitigating seizure activity, as inflammation is known to exacerbate seizure severity in certain types of epilepsy. Thus, this derivative offers a dual benefit of anti-inflammatory and anticonvulsant actions.(Elkanzi et al. 2022)
- **Chalcone Derivative 5**: This chalcone derivative, featuring a benzyl group on the B ring, has demonstrated significant efficacy in reducing seizure activity in animal models. The benzyl substitution enhances the compound's ability to interact with biological targets involved in seizure modulation, improving its pharmacological profile and making it a promising candidate for anti-epileptic therapy.(Sharma et al. 2013)

Synthetic Chemistry of Chalcone Derivatives

Chalcones are important intermediates in the synthesis of various bioactive compounds and have garnered significant interest in medicinal chemistry due to their diverse pharmacological properties. The synthetic chemistry of chalcone derivatives involves several key pathways, including traditional methods like aldol condensation and Claisen-Schmidt reactions, as well as advanced synthesis techniques that emphasize green chemistry approaches.(Mallia and Sloop 2023)

Aldol Condensation and Claisen-Schmidt Reactions

The Claisen-Schmidt condensation is one of the most widely used methods for synthesizing chalcones. This reaction involves the condensation of an aromatic aldehyde with an acetophenone derivative in the presence of a base catalyst, typically sodium hydroxide (NaOH) or potassium hydroxide (KOH). The reaction proceeds through the formation of an enolate from the acetophenone, which then attacks the carbonyl carbon of the aldehyde, leading to the formation of the chalcone structure.(Liu et al. 2022)

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Reaction Equation:



$$C_6H_5CHO + C_6H_5COCH_3 \xrightarrow{NaOH} C_6H_5CH{=}CHCOC_6H_5 + H_2O$$

Conditions:

- Stirring at room temperature or mild heating.

The advantages of this method include its simplicity and effectiveness in producing chalcones with high yields (often between 88% and 98%). However, traditional Claisen-Schmidt reactions can have drawbacks such as prolonged reaction times and the potential for side reactions that lead to product mixtures. To address these issues, researchers have explored alternative methods, including microwave-assisted synthesis, which significantly reduces reaction times and improves yields by providing uniform heating and facilitating solvent-free conditions. For example, chalcones can be synthesized using microwave irradiation in a few minutes without solvents, resulting in high yields.

Advanced Synthesis Techniques and Green Chemistry Approaches

In recent years, there has been a growing emphasis on green chemistry approaches for chalcone synthesis to minimize environmental impact and improve efficiency. Techniques such as ultrasound-assisted synthesis and mechanochemical methods (e.g., grinding) have gained popularity due to their solvent-free nature and reduced reaction times. For instance, ultrasound irradiation can accelerate reactions, allowing for the rapid formation of chalcones with yields exceeding 95% in less than a minute.

Microwave-assisted synthesis is another advanced technique that enhances the efficiency of chalcone production by reducing energy consumption and reaction time while increasing product yields. Additionally, using ionic liquids as solvents or catalysts has been shown to facilitate solvent-free reactions, further optimizing yield and regioselectivity while minimizing waste.

One-pot synthesis methods are also being explored for their ability to streamline the process by combining multiple steps into a single reaction. This approach not only simplifies purification but also increases overall yield. For example, one-pot reactions involving primary alcohols and chromium oxide have been employed to produce furochalcones efficiently. These advanced synthetic techniques contribute to more sustainable practices in chalcone chemistry while maintaining or enhancing the productivity of traditional methods.(Marotta et al. 2022a; Rajendran et al. 2022)

Overcoming Challenges in Chalcone Synthesis: The synthesis of chalcones, while generally straightforward, presents several challenges that can affect yield, purity, and scalability. Overcoming difficulties in chalcone synthesis requires innovative approaches that enhance yield, purity, and sustainability. By adopting advanced techniques such as microwave-assisted synthesis, sonication, green chemistry principles, and one-pot reactions, researchers can significantly improve the efficiency of chalcone production while minimizing environmental impact.(Paul et al. 2023)

Limitations of Conventional Methods

Traditional methods for synthesizing chalcones, such as the Claisen-Schmidt condensation, often require specific conditions that can lead to suboptimal yields and lengthy reaction times. For example, using strong bases like sodium hydroxide (NaOH) in polar solvents can result in varying yields depending on the substituents present in the reactants. Additionally, purification processes such as column chromatography or recrystallization may be necessary to isolate the desired product, contributing to longer synthesis times and increased costs. (Paul et al. 2023; Valipour 2022)

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Innovative Approaches to Enhance Yield and Purity

Microwave-Assisted Synthesis

Microwave-assisted synthesis has emerged as a powerful technique to improve the efficiency of chalcone production. This method significantly reduces reaction times and enhances yields by providing uniform heating. For instance, a study demonstrated that microwave irradiation could yield chalcones in high purity within minutes, compared to several hours using conventional heating methods. However, scalability remains a concern as microwave techniques may not be easily adaptable for large-scale production.

- **Sonication Techniques:** Sonication has also been employed to enhance the solubility of reactants and improve reaction rates. Researchers have reported increased yields by utilizing ultrasonic waves due to better homogenization of solid reactants in the reaction mixture. For example, a study indicated that using a sonicator bath improved yields from 56% to 100% in just 10 minutes of reaction time when synthesizing chalcones from aromatic aldehydes and acetophenones.
- **Green Chemistry Approaches:** The adoption of green chemistry principles has led to the development of more sustainable synthetic methodologies for chalcone synthesis. These approaches aim to minimize environmental impact while maintaining or enhancing yield and purity.(Donaire-Arias et al. 2023; Valipour 2022)

Solvent-Free Methods

One significant advancement is the use of solvent-free methods such as grinding techniques or mechanochemical synthesis. In these methods, solid reactants are ground together with a base catalyst (e.g., sodium hydroxide) to promote the condensation reaction without the need for solvents. This approach not only reduces waste but also simplifies purification processes. Studies have shown that solvent-free grinding methods yield chalcones with excellent efficiency and minimal environmental impact **Use of Alternative Solvents.**

When solvents are necessary, researchers have explored less toxic alternatives such as glycerol or ionic liquids, which can provide comparable or improved yields without the environmental drawbacks associated with traditional organic solvents. For example, glycerol has been used effectively as a solvent in chalcone synthesis, leading to higher yields compared to conventional polar solvents.(Marotta et al. 2022)

One-Pot Synthesis Techniques

One-pot synthesis strategies have gained popularity for their ability to streamline the synthetic process by combining multiple steps into a single reaction. This method reduces the need for intermediate purifications and enhances overall yield. For instance, one-pot reactions involving primary alcohols and chromium oxide have been utilized to efficiently produce furochalcones with high yields.(Paul et al. 2023; Marotta et al. 2022)

Toxicology and Safety Evaluation of Chalcone Derivatives

Chalcone derivatives have garnered significant attention due to their diverse biological activities, including anti-inflammatory, anticancer, and antimicrobial properties. However, evaluating their safety and potential toxicity is essential for their development as therapeutic agents. The toxicology and safety evaluation of chalcone derivatives are essential steps in their development as therapeutic agents. Identifying potential toxicophores allows researchers to understand the risks associated with these compounds, while strategic chemical modifications can help mitigate toxicity without compromising efficacy. Continued research in this area will contribute to the safe application of chalcone derivatives in clinical settings.(Marotta et al. 2022)

Identification of Potential Toxicophores

The identification of toxicophores in chalcone derivatives is critical for assessing their safety profiles. Toxicophores are specific molecular fragments that are associated with adverse biological effects. Research has shown that certain structural features in chalcones can contribute to toxicity, including the presence of reactive functional groups such as α, and β-unsaturated carbonyl systems, which may lead to the formation of reactive oxygen species (ROS) and subsequent cellular damage.(George et al. 2022) Studies have indicated that substituents on the aromatic rings can significantly influence the toxicity of chalcone derivatives; for instance, electron-withdrawing groups (EWGs) may enhance toxicity by stabilizing reactive intermediates, while electron-donating groups (EDGs) may reduce it by destabilizing these intermediates.(Dhaliwal et al. 2022) The lipophilicity of chalcones, often measured by logP values, plays a crucial role in their ability to cross cell membranes and potentially accumulate in tissues, leading to increased toxicity.(Ouyang et al. 2021)

Chemical Modifications to Reduce Toxicity

Chemical modifications to chalcone derivatives can effectively reduce toxicity while maintaining or enhancing their pharmacological activity. One common strategy involves altering substituents on the aromatic rings to optimize their electronic properties. For example, introducing hydroxyl (-OH) or methoxy (-OCH_3) groups can improve solubility and reduce toxicity by facilitating better metabolic clearance.(Okolo et al. 2021) Additionally, the incorporation of heterocyclic moieties has been shown to enhance biological activity while mitigating adverse effects. For instance, chalcones modified with pyridine or imidazole rings have demonstrated improved safety profiles in various biological assays [4]. Structural

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

modifications that lower lipophilicity can also decrease toxicity by reducing membrane permeability and accumulation in non-target tissues.(Ouyang et al. 2021) The use of prodrug strategies, where a less active form of the compound is administered and converted into an active form within the body, can further enhance safety by minimizing exposure to potentially harmful intermediates.(Dhaliwal et al. 2022) Recent studies have highlighted the importance of optimizing both efficacy and safety through careful design and modification of chalcone structures, ensuring a balanced therapeutic profile.(George et al. 2022)

Comparative Analysis: Chalcone-Based vs. Conventional Anti-Epileptic Agents

Chalcone derivatives reveal their potentiality for epilepsy treatment as a new generation of therapy compared to the traditional AEDs. New chalcone derivatives may be a useful replacement for standard anti-epileptic preparations because of their structure that allows to design of preparations with selective action. Of course, additional investigations are required to confirm the effectiveness and safety of chalcones in comparison with conventional medications; nonetheless, the possibility of changing chalcones' structure can be considered a promising direction in the development of antiepileptic drugs. Chalcones contain α,β-unsaturated carbonyl moiety that makes them susceptible to structural variations with the view of improving their pharmacological properties.(Gomes et al. 2017). This kind of arrangement ensures that chalcones are able to start reactions with quite a number of biological activities, including targeting ion channels as well as neurotransmitter receptors, which control neuronal excitability. , on the other hand, offers a less specific and morphologically rigid drug molecule with non-scientific use reserves predominantly known to target neuronal membranes or deployment of GABAergic transmission. Chalcones have variable structural options based on the different substituents at the aromatic rings, including the lipophilic and bioavailability that in some way affect the therapeutic value. For example, the introduction of hydroxyl or methoxy further increases the anticonvulsant activity of particular chalcone as a result of their effectiveness on the GABA receptors or on voltage-gated sodium channels. Such flexibility in modification is not as clearly seen in conventional AEDs, as these compounds have rigid structures that afford them relatively low versatility in terms of alteration for therapeutic purposes.

Table 3: Comparative Analysis of Chalcone Derivatives and Standard Drugs

Feature	Chalcone Derivatives	Conventional AEDs
Chemical Structure	α,β-unsaturated carbonyl system with aryl rings	Rigid structures with specific functional groups
Mechanism of Action	Multiple targets (ion channels, receptors)	Stabilization of membranes; GABA enhancement
Modifiability	High; versatile substituent options	Limited; fixed structures
Efficacy	Variable; some show superior activity	Established efficacy in epilepsy treatment
Safety Profile	Potentially lower toxicity with modifications	Known side effects; variable tolerability

Comparative Efficacy of Chalcones vs. Conventional Anti-Epileptic Drugs

Chalcone derivatives have attracted interest as new sources of AED due to their chemically novel structural features and biological profiles. Chalcone derivatives are a potent weapon against typical anti-epileptic agents since they introduce a novel approach to the pharmacological modifying of the structure. The available in vitro data show promising trends for potency and selectivity coupled with lesser toxicity than conventional AEDs; therefore, more careful clinical trials are warranted. Further investigation of the SAR of chalcone derivatives is expected to be important in the design of potential anti-epileptic drugs.(Gomes et al. 2017)



REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Evaluation of Potency and Selectivity

Structural variations of chalcone derivatives modify their action profiles in a way that affects their antiepileptic efficiency and specificity. Different researchers have also pointed out that certain chalcones do interact with ion channels including sodium and calcium making the former influence the latter when it comes to the excitability of neurons For instance, chalcone derivatives have shown promising antiepileptic efficacy in some animal models; some the prepared drugs are potent enough to be comparable to standard AEDs such as phenytoin and carbamazepine. Furthermore, because the structures of chalcones can be altered, selectivity with regard to certain targets may be increased over that of more general AEDs, which minimizes the likeliness of side effects linked to non-specific activity. On the other hand, traditional AEDs are generally understood to have specific actions and mechanisms: increasing the action of GABA or stabilizing neuronal membranes. (Tukur et al. 2022b). That is why these drugs help to control seizures, but they are restricted in the spectrum of seizures they effectively treat, as well as the side effects they can produce. Such flexibility in the structure of chalcone derivatives might be a benefit in the creation of comparably targeted therapies that can overcome these drawbacks.

Chalcones' Side Effects and Toxicity Profile

Importantly, the safety profile of chalcone derivatives is an important factor that is central to the therapeutic prospects of these compounds. In initial experimentations, small numbers of chalcones seem to have less toxicity compared with current AEDs, the latter of which are known to severely incapacitate patients through side- effects such as; sedation, weight gain, and cognitive impairment. For example, the study done on various synthetic chalcones showed that some of the derivatives are safer as they have LD_{50} greater than 550 mg/kg in an animal model (MeSH NLM). (Sinha et al. 2019)Toxicological studies have shown that changes in chalcones and their derivatives have reduced harms more effectively than the normal AEDs that are described with severe side effects which are potentially dangerous to patient's compliance and quality of life. For instance, valproate and lamotrigine some of the model drugs are associated with side-effects such as obesity and mood swings respectively. The potential for altering chalcone structures in terms of potency may open new avenues in the design and synthesis of new antiepileptic drugs with fewer untoward effects affecting metabolism as major side issues. (E. Perucca and Meador 2005; Cancino et al. 2021)

Table 4: Comparison of Chalcone Derivatives and Conventional Anti-Epileptic Medications

Feature	Chalcone Derivatives	Conventional AEDs
Mechanism of Action	Modulation of ion channels; multiple targets	Stabilization of membranes; GABA enhancement
Potency	Variable; some comparable to established AEDs	Established efficacy
Selectivity	High; can be tailored through modifications	Limited; broader spectrum
Side Effects	Generally lower; modifications can reduce toxicity	Common side effects (e.g., sedation)
Toxicity Profile	Lower toxicity reported in studies	Known toxicities; variable tolerability

Synthetic Approaches for Chalcone Derivatives with Enhanced Activity

A new class of chalcone derivatives is attractive to medicinal chemists since they show a wide range of biological actions such as inflammation suppression, anticancer effects, and anticonvulsant activity. This Section describes different synthetic methodologies and approaches used in modifying chalcone derivatives for increased activity, in addition to methods used to optimize these compounds for activity. New synthetic approaches and optimization strategies to obtain new chalcone derivatives with improved activity are essential. Using new methodologies, and methods such as microwave synthesis, one-pot reactions, and molecular hybridization affords scientists an opportunity to design better therapeutic agents. Further elucidation of structure-activity relationship studies will be essential in enhancing the chalcone derivatives drug discovery process.(Marotta et al. 2022c)

Synthetic Pathways and Techniques

The synthesis of chalcone derivatives mainly consists of Claisen-Schmidt condensation comprising of the reaction of an aromatic aldehyde and a ketone, in most cases being Acetophenone with a base as a catalyst. This method is preferred because of its ability to provide α, and β unsaturated carbonyl compounds efficiently and easily. (Tukur et al. 2022). The reaction can be carried out under different conditions, such as microwave synthesis where the reaction time is drastically cut down, and yield enhanced.

Another inventive approaches include one-pot transformations which mean that the series of reactions are combined in the same container. This approach also improves yield as well as minimizes purification procedures.(Marotta et al. 2022) Moreover, phase transfer catalysis has been employed to synthesize chalcones with heterocyclic systems where the biological activity is potentially facilitated by the addition of new substituents.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Solvent-free methods and mechanochemical processes including grinding as well as ball milling have developed as green practices that minimize the use of solvents and maximize the yield of the product. These methods largely contribute to a shorter reaction time and lesser formation of side products which makes them suitable when synthesising chalcone derivatives with highly active profiles.(Mezgebe, Melaku, and Mulugeta 2023; Marotta et al. 2022)

1. Reaction Pathways for Chalcone Derivative Synthesis

Chalcone derivatives are synthesized via modifications to the Claisen-Schmidt condensation reaction. The addition of functional groups or heterocycles to the aromatic rings or the propenone system enhances their biological activity

a. Reaction Pathway for Hydroxychalcone Derivative

Reaction Scheme:



$$\text{Hydroxybenzaldehyde} + \text{Acetophenone} \xrightarrow{\text{NaOH, Ethanol}} \text{4-Hydroxychalcone} + H_2O$$

Reaction Steps:

1. **Step 1**: Benzaldehyde reacts with acetophenone in the presence of NaOH.
2. **Step 2**: NaOH deprotonates the α-carbon of acetophenone, forming an enolate ion.
3. **Step 3**: The enolate ion attacks the carbonyl carbon of benzaldehyde, forming a β-hydroxyketone intermediate.
4. **Step 4**: The intermediate undergoes dehydration to form the final product, chalcone, along with water as a byproduct.

b. Reaction Pathway for Hybrid Chalcones with Imidazole

Reaction:



$$\text{Benzaldehyde} + \text{Imidazole-Acetophenone} \xrightarrow{\text{NaOH, Ethanol}} \text{Imidazole-Chalcone} + H_2O$$

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Reaction Steps:
1. **Step 1**: Benzaldehyde reacts with imidazole-acetophenone in the presence of NaOH.
2. **Step 2**: NaOH deprotonates the α-carbon of the imidazole-acetophenone, forming an enolate ion.
3. **Step 3**: The enolate ion attacks the carbonyl carbon of benzaldehyde, forming a β-hydroxyketone intermediate.
4. **Step 4**: The intermediate undergoes dehydration to form the final product, Imidazole-Chalcone, along with water as a byproduct.

2. Hybrid Chalcone Structures Incorporating Heterocycles
Hybrid chalcones integrate pharmacophores, such as imidazole, pyridine, or furan, into the B ring to create derivatives with enhanced pharmacological properties.



Imidazolyl Chalcone



2-Pyridyl Chalcone



2-Furyl Chalcone

a. Imidazole-Containing Chalcone
Structure:
Imidazole-containing chalcones are characterized by an imidazole moiety attached to the para position of the B ring. The imidazole group contributes hydrophilic properties and electron-donating capabilities, enabling these derivatives to interact effectively with biological receptors and enzymes.

Applications:
- **Anticonvulsant Activity:** Imidazole chalcones exhibit strong interactions with GABA_A receptors, enhancing inhibitory neurotransmission. They also stabilize sodium channels in their inactivated state, reducing excessive neuronal excitability, which is beneficial in controlling seizures.
- **Anti-inflammatory Activity:** These compounds inhibit inflammatory mediators, including cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, reducing prostaglandin and leukotriene synthesis.
- **Antifungal Activity:** The imidazole group disrupts fungal cell membrane integrity by inhibiting enzymes involved in ergosterol biosynthesis, an essential component of fungal membranes.

Advantages:
Imidazole chalcones offer high receptor-binding affinity, enhanced water solubility, and dual functionality, making them versatile for various therapeutic applications.(Elkanzi et al. 2022; Tukur et al. 2022b)

b. Pyridine-Substituted Chalcone
Structure:
Pyridine-substituted chalcones contain a pyridine ring replacing the B ring. The presence of a nitrogen atom in the pyridine ring introduces electron-withdrawing properties and hydrogen bond acceptor sites, making these derivatives highly interactive with enzymes and proteins.

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1(2024)
http://www.veterinaria.org
Article Received: 30/05/2024 Revised: 09/06/2024 Accepted: 20/06/2024

Applications:

- **Antimicrobial Properties:** Pyridine chalcones demonstrate significant activity against bacterial and fungal pathogens. The nitrogen atom enhances interactions with microbial enzymes, disrupting metabolic pathways essential for cell survival.
- **Anticancer Potential:** These derivatives exhibit cytotoxicity against cancer cells by interfering with signaling pathways and inducing apoptosis. Pyridine's electron density can improve binding to active sites of kinase enzymes.
- **Anti-inflammatory Effects:** Pyridine chalcones modulate the activity of inflammatory cytokines, reducing oxidative stress and inflammation.

Advantages:

The pyridine moiety enhances metabolic stability and increases the overall lipophilicity of chalcones, improving their membrane permeability and bioavailability.

c. Furan-Containing Chalcone

Structure:

Furan-containing chalcones feature a furan ring as the B ring, which is an electron-rich heterocycle that improves the compound's reactivity and antioxidant properties.

Applications:

- **Antioxidant Activity:** Furan chalcones scavenge reactive oxygen species (ROS) effectively due to the electron-rich nature of the furan ring. They help in reducing oxidative damage in cells, making them valuable in treating neurodegenerative and cardiovascular diseases.
- **Antimicrobial Activity:** The furan ring enhances interactions with microbial enzymes, leading to the disruption of bacterial and fungal cellular processes.
- **Neuroprotective Effects:** Furan chalcones protect neuronal cells from oxidative stress-induced damage, making them potential candidates for managing Alzheimer's and Parkinson's diseases.

Advantages:

The furan moiety contributes to the compound's electron density, enhancing interactions with reactive species and biological targets. Furan chalcones also show good metabolic stability and pharmacokinetic profiles.

Optimization of Derivatives for Improved Efficacy

Promising chalcone derivatives with enhanced potency are the result of modifications in the chemical makeup of these compounds. Substituents have been introduced on the aromatic rings to improve their binding affinity to the biological targets. For instance, groups of hydroxyls (-OH) or methoxy (-OCH_3) could highly increase solubility and bioavailability as well as Moreover, pharmacological activity.(Gaonkar and Vignesh 2017). Heterocyclic extensions can improve the activity of the chalcone-based compounds for specific targets to a significant extent. For example, pyrrole- or imidazole-containing chalcones appear to have shown positive preclinical results because of their improved selective toxicity. Moreover, the application of molecular hybridization approaches can generate new hybrids from two or more useful pharmacophores making the enhanced therapeutic agents possible. A relatively modern important improvement in drug design is also a computer-aided drug design that also contributes much to developing the optimal chalcone derivatives. These computational techniques facilitate estimates in regard to changes in the constraints formed by biological activity and are useful in design procedures (MeSH NLM). Thus, several key structural features that seem to be related to activity can be pinpointed by chemists, so that modifications of chalcones can be made to maximize beneficial effects on health and minimize negative impacts at an organic compound level.(Ávila et al. 2008; Marotta et al. 2022c)

Challenges and Future Directions in Chalcone-Based Anti-Epileptic Drug Development

Chalcone derivatives are considered one of the potential candidates for the development of new anti-epileptic drugs because of their multilateral activity profiles. Nonetheless, several issues must be resolved to enable them to advance to the clinical stage. The present section underlines the recent issues and concerns regarding clinical development, recent findings related to a combination of therapies, and the issues related to the regulation of new chalcone compounds. There is considerable potential for chalcone derivatives as antiepileptic compounds, although several issues must be solved for this to happen. These challenges will be important to address through sustained research efforts of combination therapies as well as structure optimization. In addition, attention to regulatory guidelines will guarantee that new chalcone compounds can reach pre-clinical studies issues and become of great clinical value. (Gomes et al. 2017)

Current Challenges in Clinical Development

All the same, the findings suggest that chalcone derivatives possess therapeutic potential, although their clinical pursuit is hampered by several factors. A cause for concern is the fact that the α,β -unsaturated carbonyl system in chalcone

molecules is comedate electrophiles. This reactivity causes the formation of covalent bonds with biological macromolecules hence causing undesirable effects for instance allergenic reactions, carcinogenicity, and mutagenicity. (Maronpot 2015) The versatility of the target profile in chalcones creates the practical challenge that such compounds can interact with other targets and cause side effects.(Tukur et al. 2022)
Moreover, structure-activity relationship studies suggest that the pharmacokinetics of chalcones require further enhancement to their bioavailability and metabolic stability. A wide range of chalcone derivatives have low solubility and bioavailability and are metabolized quickly, which has been reported to affect their ability to work in vivo. (Mezgebe, Melaku, and Mulugeta 2023c)

Emerging Research and Potential for Combination Therapies
The new study's suggestions point to the fact that anticonvulsant effects of chalcone derivatives are pronounced when the administration of the compound is accompanied by other antiepileptic agents or other types of medicine. Some chalcones were found to be complementary to the usual AEDs by acting synergistically The matters of concern about chalcones and. For instance, the synthesis of chalcones along with sodium channel blockers or GABAergic agents may be anticipated in seizure control and treatment than using the agents separately because the chalcones affect additional pathways in neuronal excitability apart from the targets of the sodium channel blockers or GABPAergic agents.(Ouyang et al. 2021) New studies about molecular hybridization approaches demonstrate that the design and synthesis of hybrid compounds with chalcone pharmacophores combined with other pharmacophores may lead to new agents with improved antiepileptic activity and reduced side effects. This approach not only increases the therapeutic effectiveness of chalcones but also solves the problems of their safety concerns by providing more controlled interactions with biological objectives.

Regulatory Considerations for Novel Anti-Epileptic Chalcone Compounds
The current regulatory model for the development of new drugs for epilepsy brings yet other complications for chalcone-based anti-epileptic agents, too. The administrative bodies before approving new compounds for clinical use demand safety, efficacy, and quality information. Since there are some concerns regarding the toxicity of some chalcone derivatives most preclinical studies should always undergo a safety evaluation. (Okolo et al. 2021)Proper regulatory acceptance of the pharmacokinetic and pharmacodynamic prole will also be possible. Included in this is awareness of the ADME properties of chalcone derivatives. Also, some questions that are related to drug-drug interactions will be also crucial for possible prevention or resolution during the process of patients' treatment.(Marotta et al. 2022)

Conclusion:
Chalcones must be considered as a new promising group of AEDs since it has various structural and pharmacological benefits compared to traditional remedies. By influencing primary neurological circuits such as the GABAergic system and ion channels they have the potential to fill the existing gaps and niches in epilepsy treatment, especially for refractory epilepsy. Furthermore, the related chalcone derivatives are further modifiable, as it is potentially possible to optimize their pharmacological activities, including efficacy and safety, as well as their absorption characteristics. The impression gained from this review re-emphasizes the prospects of chalcones as an underlying framework for novel epilepsy treatments. The synthesis aspect like green synthetic protocols or hybrid approaches has increased the potential of chalcone and preclinical evidence displays the efficacy of chalcone in minimizing seizure activity with less adverse effects than conventional AEDs. Nevertheless, there are still some issues in enhancing the pharmacokinetics of these nano drugs, avoiding deleterious effects on living organisms, and passing through bureaucratic barriers necessary for application in clinics. Further studies should envision finding the relationship of different chalcone structures with their activity, optimizing their properties as drugs, and including them with other drugs for dual treatment to get the best results. Continual research in these directions indicates the fact that chalcones have great promise in changing the treatment spectrum of epilepsy for the better for millions of patients around the globe.

Reference
1. Aksöz, Begüm Evranos, and Rahmiye Ertan. 2011. "Chemical and Structural Properties of Chalcones I." *J. Pharm. Sci*. Vol. 36.
2. Alka N. Choudhary, Arun Kumar, and Vijay Juy. 2012. "Design, Synthesis and Evaluation of Chalcone Derivatives as Anti- Inflammatory, Antioxidant and Antiulcer Agents." *Letters in Drug Design & Discovery* 9 (5): 479–88. https://doi.org/10.2174/157018012800389368.
3. Ávila, Hugo Pereira, Elza de Fátima Albino Smânia, Franco Delle Monache, and Artur Smânia. 2008. "Structure-Activity Relationship of Antibacterial Chalcones." *Bioorganic & Medicinal Chemistry (Print)* 16 (22): 9790–94. https://doi.org/10.1016/j.bmc.2008.09.064.
4. Benarroch, Eduardo. 2021. "What Is the Role of GABA Transporters in Seizures?" *Neurology* 97 (12): 580–84. https://doi.org/10.1212/WNL.0000000000012574.
5. Cancino, Karina, Inés Castro, Carlos Yauri, Valérie Jullian, Jorge Arévalo, Michel Sauvain, Vanessa Adaui, and Denis Castillo. 2021. "Toxicity Assessment of Synthetic Chalcones with Antileishmanial Potential in BALB/c

Mice." *Revista Peruana de Medicina Experimental y Salud Pública* 38 (3): 424–33. https://doi.org/10.17843/RPMESP.2021.383.6937.
6. Catterall, William A. 2014. "Sodium Channels, Inherited Epilepsy, and Antiepileptic Drugs." *Annual Review of Pharmacology and Toxicology* 54:317–38. https://doi.org/10.1146/ANNUREV-PHARMTOX-011112-140232.
7. Depondt, Chantal. 2006. "The Potential of Pharmacogenetics in the Treatment of Epilepsy." *European Journal of Paediatric Neurology* 10 (2): 57–65. https://doi.org/10.1016/j.ejpn.2005.11.009.
8. Dhaliwal, Jagjit Singh, Said Moshawih, Khang Wen Goh, Mei Jun Loy, Md Sanower Hossain, Andi Hermansyah, Vijay Kotra, et al. 2022a. "Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives." *Molecules 2022, Vol. 27, Page 7062* 27 (20): 7062. https://doi.org/10.3390/MOLECULES27207062.
9. Donaire-Arias, Ana, Martin L. Poulsen, Jaime Ramón-Costa, Ana Maria Montagut, Roger Estrada-Tejedor, and José I. Borrell. 2023. "Synthesis of Chalcones: An Improved High-Yield and Substituent-Independent Protocol for an Old Structure." *Molecules* 28 (22): 7576. https://doi.org/10.3390/MOLECULES28227576.
10. Elkanzi, Nadia A.A., Hajer Hrichi, Ruba A. Alolayan, Wassila Derafa, Fatin M. Zahou, and Rania B. Bakr. 2022. "Synthesis of Chalcones Derivatives and Their Biological Activities: A Review." *ACS Omega* 7 (32): 27769. https://doi.org/10.1021/ACSOMEGA.2C01779.
11. Fritschy, Jean Marc. 2008. "Epilepsy, E/I Balance and GABAA Receptor Plasticity." *Frontiers in Molecular Neuroscience* 1 (MAR): 201. https://doi.org/10.3389/NEURO.02.005.2008/BIBTEX.
12. Gaonkar, Santosh L., and U. N. Vignesh. 2017. "Synthesis and Pharmacological Properties of Chalcones: A Review." *Research on Chemical Intermediates* 43 (11): 6043–77. https://doi.org/10.1007/S11164-017-2977-5.
13. George, Ginson, Vishal Payyalot Koyiparambath, Sunitha Sukumaran, Aathira Sujathan Nair, Leena K. Pappachan, Abdullah G. Al-Sehemi, Hoon Kim, and Bijo Mathew. 2022. "Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors." *International Journal of Molecular Sciences* 23 (6): 3121. https://doi.org/10.3390/IJMS23063121.
14. Go, M., X. Wu, and X. Liu. 2005. "Chalcones: An Update on Cytotoxic and Chemoprotective Properties." *Current Medicinal Chemistry* 12 (4): 483–99. https://doi.org/10.2174/0929867053363153.
15. Gomes, Marcelo N., Eugene N. Muratov, Maristela Pereira, Josana C. Peixoto, Lucimar P. Rosseto, Pedro V.L. Cravo, Carolina H. Andrade, and Bruno J. Neves. 2017. "Chalcone Derivatives: Promising Starting Points for Drug Design." *Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry* 22 (8): 1210. https://doi.org/10.3390/MOLECULES22081210.
16. Issaoui, Ahmad, and Ferhat Koçak. 2023. "The Treatment of Epilepsy." *Actualites Pharmaceutiques* 62 (627): 39–44. https://doi.org/10.1016/j.actpha.2023.03.047.
17. Liu, Wenjing, Min He, Yongjun Li, Zhiyun Peng, and Guangcheng Wang. 2022. "A Review on Synthetic Chalcone Derivatives as Tubulin Polymerisation Inhibitors." *Journal of Enzyme Inhibition and Medicinal Chemistry* 37 (1): 9–38. https://doi.org/10.1080/14756366.2021.1976772.
18. Lu, Xi, Yong Yang, Ruijiao Zhou, Yun Li, Yi Yang, and Xuefeng Wang. 2019. "Protrudin Modulates Seizure Activity through GABAA Receptor Regulation." *Cell Death & Disease 2019 10:12* 10 (12): 1–13. https://doi.org/10.1038/s41419-019-2118-8.
19. Mahapatra, Debarshi Kar, Sanjay Kumar Bharti, and Vivek Asati. 2017. "Chalcone Derivatives: Anti-Inflammatory Potential and Molecular Targets Perspectives." *Current Topics in Medicinal Chemistry* 17 (28): 3146–69. https://doi.org/10.2174/1568026617666170914160446.
20. Mallia, Ajay, and Joseph Sloop. 2023. "Advances in the Synthesis of Heteroaromatic Hybrid Chalcones." *Molecules 2023, Vol. 28, Page 3201* 28 (7): 3201. https://doi.org/10.3390/MOLECULES28073201.
21. Maronpot, Robert R. 2015. "Toxicological Assessment of Ashitaba Chalcone." *Food and Chemical Toxicology* 77 (March):111–19. https://doi.org/10.1016/J.FCT.2014.12.021.
22. Marotta, Ludovica, Sara Rossi, Roberta Ibba, Simone Brogi, Vincenzo Calderone, Stefania Butini, Giuseppe Campiani, and Sandra Gemma. 2022a. "The Green Chemistry of Chalcones: Valuable Sources of Privileged Core Structures for Drug Discovery." *Frontiers in Chemistry* 10 (September):988376. https://doi.org/10.3389/FCHEM.2022.988376/BIBTEX.
23. Meldrum, Brian S. 1996. "Update on the Mechanism of Action of Antiepileptic Drugs." *Epilepsia* 37 Suppl 6 (SUPPL. 6). https://doi.org/10.1111/J.1528-1157.1996.TB06038.X.
24. Mezgebe, Kibrom, Yadessa Melaku, and Endale Mulugeta. 2023a. "Synthesis and Pharmacological Activities of Chalcone and Its Derivatives Bearing N-Heterocyclic Scaffolds: A Review." *ACS Omega*. American Chemical Society. https://doi.org/10.1021/acsomega.3c01035.
25. Mohamed, Mamdouh F.A., and Gamal El Din A. Abuo-Rahma. 2020. "Molecular Targets and Anticancer Activity of Quinoline–Chalcone Hybrids: Literature Review." *RSC Advances* 10 (52): 31139–55. https://doi.org/10.1039/D0RA05594H.
26. Moreira, Joana, Joana Almeida, Lucília Saraiva, Honorina Cidade, and Madalena Pinto. 2021. "Chalcones as Promising Antitumor Agents by Targeting the P53 Pathway: An Overview and New Insights in Drug-Likeness." *Molecules 2021, Vol. 26, Page 3737* 26 (12): 3737. https://doi.org/10.3390/MOLECULES26123737.

27. Okolo, Emelda N., David I. Ugwu, Benjamin E. Ezema, Joseph C. Ndefo, Florence U. Eze, Chidimma G. Ezema, James A. Ezugwu, and Oguejiofo T. Ujam. 2021. "New Chalcone Derivatives as Potential Antimicrobial and Antioxidant Agent." *Scientific Reports 2021 11:1* 11 (1): 1–13. https://doi.org/10.1038/s41598-021-01292-5.
28. Olsen, Richard W., and Werner Sieghart. 2009. "GABA A Receptors: Subtypes Provide Diversity of Function and Pharmacology." *Neuropharmacology* 56 (1): 141–48. https://doi.org/10.1016/J.NEUROPHARM.2008.07.045.
29. Ouyang, Yang, Juanjuan Li, Xinyue Chen, Xiaoyu Fu, Si Sun, and Qi Wu. 2021. "Chalcone Derivatives: Role in Anticancer Therapy." *Biomolecules 2021, Vol. 11, Page 894* 11 (6): 894. https://doi.org/10.3390/BIOM11060894.
30. Paul, Rahit, Saikat Sen, Debalina Adak, Ankita Porey, and Shaileyee Das. 2023. "A Review: Green Synthesis of Chalcone." *Tuijin Jishu/Journal of Propulsion Technology*. Vol. 44.
31. Perucca, E., and K. J. Meador. 2005. "Adverse Effects of Antiepileptic Drugs." *Acta Neurologica Scandinavica. Supplementum* 181 (s181): 30–35. https://doi.org/10.1111/J.1600-0404.2005.00506.X.
32. Perucca, Emilio, Meir Bialer, and H. Steve White. 2023. "New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System." *CNS Drugs* 37 (9): 755–79. https://doi.org/10.1007/S40263-023-01027-2.
33. Perucca, Emilio, H. Steve White, and Meir Bialer. 2023. "New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development." *CNS Drugs* 37 (9): 781–95. https://doi.org/10.1007/S40263-023-01025-4/TABLES/3.
34. Rajendran, Gayathri, Deepu Bhanu, Baladhandapani Aruchamy, Prasanna Ramani, Nanjan Pandurangan, Kondapa Naidu Bobba, Eun Jung Oh, Ho Yun Chung, Prakash Gangadaran, and Byeong Cheol Ahn. 2022. "Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry." *Pharmaceuticals* 15 (10): 1250. https://doi.org/10.3390/PH15101250.
35. Richardson, Robert J., Steven Petrou, and Alexander Bryson. 2024. "Established and Emerging GABAA Receptor Pharmacotherapy for Epilepsy." *Frontiers in Pharmacology* 15 (February):1341472. https://doi.org/10.3389/FPHAR.2024.1341472/BIBTEX.
36. Salehi, Bahare, Cristina Quispe, Imane Chamkhi, Nasreddine El Omari, Abdelaali Balahbib, Javad Sharifi-Rad, Abdelhakim Bouyahya, et al. 2021. "Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence." *Frontiers in Pharmacology* 11 (January):592654. https://doi.org/10.3389/FPHAR.2020.592654/BIBTEX.
37. Schmidt, Dieter. 2009a. "Drug Treatment of Epilepsy: Options and Limitations." *Epilepsy & Behavior* 15 (1): 56–65. https://doi.org/10.1016/J.YEBEH.2009.02.030.
38. Schmidt, Dieter, and Steven C. Schachter. 2014. "Drug Treatment of Epilepsy in Adults." *BMJ (Online)* 348 (February). https://doi.org/10.1136/BMJ.G254.
39. Sharma, C S, K S Shekhawat, C S Chauhan, and Neeraj Kumar. 2013. "Synthesis and Anticonvulsant Activity of Some Chalcone Derivatives." *Available Online Www.Jocpr.Com Journal of Chemical and Pharmaceutical Research*, no. 5, 450–54. www.jocpr.com.
40. Shorvon, Simon D. 2011. "The Etiologic Classification of Epilepsy." *Epilepsia* 52 (6): 1052–57. https://doi.org/10.1111/J.1528-1167.2011.03041.X.
41. Sinha, Shweta, Daniela I. Batovska, Bikash Medhi, B. D. Radotra, Ashish Bhalla, Nadezhda Markova, and Rakesh Sehgal. 2019. "In Vitro Anti-Malarial Efficacy of Chalcones: Cytotoxicity Profile, Mechanism of Action and Their Effect on Erythrocytes." *Malaria Journal* 18 (1): 1–11. https://doi.org/10.1186/S12936-019-3060-Z/FIGURES/5.
42. Tomás-Barberán, Francisco A., and Michael N. Clifford. 2000. "Flavanones, Chalcones and Dihydrochalcones - Nature, Occurrence and Dietary Burden." *Journal of the Science of Food and Agriculture*. https://doi.org/10.1002/(SICI)1097-0010(20000515)80:7<1073::AID-JSFA568>3.0.CO;2-B.
43. Treiman, David M. 2001. "GABAergic Mechanisms in Epilepsy." *Epilepsia* 42 Suppl 3 (SUPPL. 3): 8–12. https://doi.org/10.1046/J.1528-1157.2001.042SUPPL.3008.X.
44. Tukur, Abdul Razaq, James Dama Habila, Rachael Gbekele Oluwa Ayo, and Ogunkemi Risikat Agbeke Lyun. 2022a. "Synthesis, Reactions and Pharmacological Applications of Chalcones and Their Derivatives- A Mini Review." *Journal of Chemical Reviews* 4 (2): 100–119. https://doi.org/10.22034/JCR.2022.326696.1143.
45. Valipour, Mehdi. 2022. "Recruitment of Chalcone's Potential in Drug Discovery of Anti-SARS-CoV-2 Agents." *Phytotherapy Research* 36 (12): 4477. https://doi.org/10.1002/PTR.7651.
46. Verma, S., A. K. Srivastava, and O. P. Pandey. 2018. "A Review on Chalcones Synthesis and Their Biological Activity." *Pharmatutor* 6 (2): 22. https://doi.org/10.29161/PT.V6.I2.2018.22.
47. Waris, Abdul, Muhammad Siraj, Ayyaz Khan, Junyu Lin, Muhammad Asim, and Fahad A. Alhumaydh. 2024. "A Comprehensive Overview of the Current Status and Advancements in Various Treatment Strategies against Epilepsy." *ACS Pharmacology and Translational Science*. https://doi.org/10.1021/ACSPTSCI.4C00494/ASSET/IMAGES/LARGE/PT4C00494_0007.JPEG.
48. Waxman, Stephen G., and Gerald W. Zamponi. 2014. "Regulating Excitability of Peripheral Afferents: Emerging Ion Channel Targets." *Nature Neuroscience* 17 (2): 153–63. https://doi.org/10.1038/NN.3602.

49. Zhuang, Chunlin, Wen Zhang, Chunquan Sheng, Wannian Zhang, Chengguo Xing, and Zhenyuan Miao. 2017a. "Chalcone: A Privileged Structure in Medicinal Chemistry." *Chemical Reviews* 117 (12): 7762–7810. https://doi.org/10.1021/acs.chemrev.7b00020.